Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Included studies provided evidence for a heterogenous population of patients with T2DM in terms of disease background, treatment experience, background therapies, and comorbid conditions (renal impairment and CV disease)
doi:10.7150/ijbs.72528 This issue Cite Research Paper 1
Ono K, Ikeda T, Takasaki JI, Yamada M (2011) Familial Parkinson disease mutations influence -synuclein assembly
Oral (Solution) Infants and children: Initially, 50 mg/kg/day in divided doses (every 3 to 4 hours)
US$ 29.44
US$ 22.60
US$ 22.98
US$ 21.09
